Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

NCT01994057 ·Status: RECRUITING

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

NCT05536505 ·Status: RECRUITING ·Phase: PHASE2

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

NCT04206072 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Evaluate EGFR Mutation Status and Impact Factors in North China

NCT02620657 ·Status: COMPLETED

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

NCT06452433 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

NCT07314216 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC

NCT02250846 ·Status: UNKNOWN ·Phase: PHASE2

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

NCT05997719 ·Status: RECRUITING

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

NCT04322890 ·Status: RECRUITING ·Phase: PHASE2

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

NCT06634667 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

NCT06376084 ·Status: ACTIVE_NOT_RECRUITING

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

NCT02961270 ·Status: UNKNOWN ·Phase: PHASE2

A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC

NCT06422546 ·Status: RECRUITING

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

NCT00874419 ·Status: COMPLETED ·Phase: PHASE3

A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer

NCT05934461 ·Status: COMPLETED

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

NCT05284539 ·Status: RECRUITING ·Phase: PHASE2

Immunotherapy in Uncommon and 20ins EGFR-mut Lung Cancers

NCT06164574 ·Status: COMPLETED

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

NCT06786208 ·Status: NOT_YET_RECRUITING

A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection

NCT05514314 ·Status: UNKNOWN ·Phase: PHASE2

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

NCT02575560 ·Status: COMPLETED

Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

NCT04785742 ·Status: UNKNOWN ·Phase: PHASE2

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

NCT03123484 ·Status: UNKNOWN ·Phase: PHASE2

A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

NCT04830826 ·Status: COMPLETED

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

NCT03544814 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

NCT05546866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2